larazotide
Biologicalexperimental
Larazotide is a synthetic eight amino acid peptide that functions as a tight junction regulator and reverses leaky junctions to their normally closed state. It has been studied in people with coeliac disease. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Oct 31, 2018 (NCT03569007)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- HaptoglobinINHIBITOR
inhibitor - zonulin
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)C[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)CN)C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)C(C)C- Mol. weight
- 725.85 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaLarazotide ↗
- ChEMBLCHEMBL2105646 ↗
Also known as
- at-2347
- at-2347
- larazotide
- larazotide
- larazotide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03569007 | Phase 3 | Oct 31, 2018 | Innovate Biopharmaceuticals |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Innovate Biopharmaceuticals | For profit | 1 | 1 | 1 | 2018 |
1 organizations
Page 1 / 1